{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tarceva%2C+erlotinib%2C+OSI-774&page=2", "query": { "intervention": "Tarceva, erlotinib, OSI-774", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 500, "total_pages": 50, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tarceva%2C+erlotinib%2C+OSI-774&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tarceva%2C+erlotinib%2C+OSI-774&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-12T15:41:11.175Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00096265", "title": "Radiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients With Brain Metastases Secondary to Non-Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Malignant Neoplasm in the Brain", "Recurrent Non-Small Cell Lung Carcinoma", "Stage IV Non-Small Cell Lung Cancer AJCC v7" ], "interventions": [ { "name": "3-Dimensional Conformal Radiation Therapy", "type": "RADIATION" }, { "name": "Erlotinib Hydrochloride", "type": "DRUG" }, { "name": "Stereotactic Radiosurgery", "type": "RADIATION" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 126, "start_date": "2004-10-06", "completion_date": "2012-04-01", "has_results": true, "last_update_posted_date": "2018-03-09", "last_synced_at": "2026-10-12T15:41:11.175Z", "location_count": 80, "location_summary": "Scottsdale, Arizona • Burbank, California • Los Angeles, California + 67 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Burbank", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Pomona", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00096265" }, { "nct_id": "NCT01456325", "title": "A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Participants With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-Squamous Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Erlotinib", "type": "DRUG" }, { "name": "Onartuzumab (MetMab)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 494, "start_date": "2012-01", "completion_date": "2016-01", "has_results": false, "last_update_posted_date": "2016-11-02", "last_synced_at": "2026-10-12T15:41:11.175Z", "location_count": 56, "location_summary": "Chandler, Arizona • Hayward, California • Modesto, California + 47 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Hayward", "state": "California" }, { "city": "Modesto", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01456325" }, { "nct_id": "NCT00709878", "title": "Histological Characterization and Differentiation of Rash From Other Epidermal Growth Factor Receptor (EGFR) Inhibitors", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Skin Rash" ], "interventions": [ { "name": "Skin Biopsy of Skin Rash Secondary to EGFRI Use", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 32, "start_date": "2008-04", "completion_date": "2010-08", "has_results": true, "last_update_posted_date": "2015-03-17", "last_synced_at": "2026-10-12T15:41:11.175Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00709878" }, { "nct_id": "NCT00463060", "title": "Sutent and Radiation as Treatment for Limited Extent Metastatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "sunitinib malate (Sutent)", "type": "DRUG" }, { "name": "radiotherapy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Icahn School of Medicine at Mount Sinai", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2007-01", "completion_date": "2014-07", "has_results": true, "last_update_posted_date": "2018-07-18", "last_synced_at": "2026-10-12T15:41:11.175Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00463060" }, { "nct_id": "NCT00367601", "title": "Erlotinib + Bevacizumab for PS 2 Chemotherapy Naïve Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "Erlotinib", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nasser Hanna, M.D.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2006-08", "completion_date": "2008-12", "has_results": true, "last_update_posted_date": "2016-02-11", "last_synced_at": "2026-10-12T15:41:11.175Z", "location_count": 13, "location_summary": "Galesburg, Illinois • Bloomington, Indiana • Evansville, Indiana + 7 more", "locations": [ { "city": "Galesburg", "state": "Illinois" }, { "city": "Bloomington", "state": "Indiana" }, { "city": "Evansville", "state": "Indiana" }, { "city": "Fort Wayne", "state": "Indiana" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00367601" }, { "nct_id": "NCT00810719", "title": "Gemcitabine and Erlotinib in Treating Patients With Metastatic or Recurrent Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "Erlotinib", "type": "DRUG" }, { "name": "gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, Davis", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2009-04", "completion_date": "2013-12", "has_results": true, "last_update_posted_date": "2018-01-10", "last_synced_at": "2026-10-12T15:41:11.175Z", "location_count": 2, "location_summary": "Los Angeles, California • Sacramento, California", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00810719" }, { "nct_id": "NCT00738881", "title": "Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Recurrent Non-Small Cell Lung Carcinoma", "Stage IIIA Non-Small Cell Lung Cancer", "Stage IIIB Non-Small Cell Lung Cancer", "Stage IV Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Erlotinib Hydrochloride", "type": "DRUG" }, { "name": "Pemetrexed Disodium", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2008-10", "completion_date": "2014-12", "has_results": true, "last_update_posted_date": "2015-10-29", "last_synced_at": "2026-10-12T15:41:11.175Z", "location_count": 268, "location_summary": "Scottsdale, Arizona • Fort Smith, Arkansas • Antioch, California + 176 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Antioch", "state": "California" }, { "city": "Fremont", "state": "California" }, { "city": "Marysville", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00738881" }, { "nct_id": "NCT01247922", "title": "Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ependymoma" ], "interventions": [ { "name": "Erlotinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "OSI Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 4, "start_date": "2011-05-23", "completion_date": "2012-09-13", "has_results": true, "last_update_posted_date": "2024-12-06", "last_synced_at": "2026-10-12T15:41:11.175Z", "location_count": 11, "location_summary": "Birmingham, Alabama • Orange, California • Palo Alto, California + 8 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01247922" }, { "nct_id": "NCT02091141", "title": "My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neoplasms", "Solid Tumors", "Biliary Cancer", "Salivary Cancer", "Bladder Cancer" ], "interventions": [ { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Pertuzumab", "type": "DRUG" }, { "name": "Erlotinib", "type": "DRUG" }, { "name": "Vemurafenib", "type": "DRUG" }, { "name": "Cobimetinib", "type": "DRUG" }, { "name": "Vismodegib", "type": "DRUG" }, { "name": "Alectinib", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 673, "start_date": "2014-04-14", "completion_date": "2023-05-24", "has_results": true, "last_update_posted_date": "2024-07-23", "last_synced_at": "2026-10-12T15:41:11.175Z", "location_count": 60, "location_summary": "Goodyear, Arizona • Phoenix, Arizona • Springdale, Arkansas + 47 more", "locations": [ { "city": "Goodyear", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Culver City", "state": "California" }, { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02091141" }, { "nct_id": "NCT02762877", "title": "Concordance of Key Actionable Genomic Alterations as Assessed in Tumor Tissue and Plasma in Non Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Non Small Cell Lung Carcinoma" ], "interventions": [], "intervention_types": [], "sponsor": "Genomic Health®, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 140, "start_date": "2016-04", "completion_date": "2019-06-19", "has_results": true, "last_update_posted_date": "2020-11-17", "last_synced_at": "2026-10-12T15:41:11.175Z", "location_count": 9, "location_summary": "Torrance, California • Macon, Georgia • Minneapolis, Minnesota + 6 more", "locations": [ { "city": "Torrance", "state": "California" }, { "city": "Macon", "state": "Georgia" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Belleville", "state": "New Jersey" }, { "city": "Neptune City", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT02762877" } ] }